Michael ZürcherSep 4Switzerland’s Commitment to Healthcare as a Leader in Health Spending and Patent Application
Michael ZürcherJun 7Why US Biotechs have been choosing Switzerland for over 60 years: An Interview with Jacqueline Hess
Michael ZürcherApr 20Article 71 KVV: The case-by-case approach to reimburse pharmaceuticals – a Swiss specialty
Michael ZürcherFeb 15Market Access in Switzerland – or how to include medical breakthroughs on the specialties list
Michael ZürcherDec 7, 2022"Enabling collaboration among member companies is the strength and success of the shqa."
Michael ZürcherNov 2, 2022Three reasons why pharmaceutical companies should consider the Swiss healthcare market
Michael ZürcherOct 24, 2022Swizzard co-founds SMS2DACH network together with MArS (Germany) and Supersonic (Austria)
Michael ZürcherSep 14, 2022Swizzard Insight No. 5: How to bring medical breakthroughs to Switzerland faster
Michael ZürcherJun 14, 2022Swizzard’s celebrating an exciting milestone – we just signed our 10th client!
Michael ZürcherMay 11, 2022Meet David Hoffmann, member of the Board of Directors & Corporate Secretary of Swizzard Pharma AG